Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 10/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.36 |
| ▸ | HTR2A | P28223 | 4/20 | 0.36 |
| ▸ | HTR2B | P41595 | 2/20 | 0.36 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.36 |
| ▸ | HRH1 | P35367 | 1/20 | 0.31 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.31 |
| ▸ | HTR3A | P46098 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL146480 | 0.81 | SLC6A2 (0.36) | SLC6A2SLC6A3SLC6A4HTR2AHTR2B | |
| SCHEMBL3309551 | 0.81 | SLC6A2 (0.39) | SLC6A2SLC6A3SLC6A4HTR2AHTR2B | |
| SCHEMBL3306691 | 0.79 | SLC6A2 (0.41) | SLC6A2SLC6A3SLC6A4HTR2AHTR2B | |
| SCHEMBL25267337 | 0.79 | SLC6A2 (0.35) | SLC6A2SLC6A3SLC6A4HTR2AHTR2B | |
| SCHEMBL400952 | 0.78 | — | — | |
| SCHEMBL3307559 | 0.77 | HTR2A (0.39) | SLC6A2SLC6A3SLC6A4HTR2AHTR2B | |
| SCHEMBL16767730 | 0.77 | SLC6A2 (0.36) | SLC6A2SLC6A3SLC6A4HTR2AHTR2B | |
| SCHEMBL11027408 | 0.77 | ADRA2C (0.42) | SLC6A2SLC6A3SLC6A4HTR2AHTR2B | |
| SCHEMBL15173596 | 0.76 | — | — | |
| SCHEMBL299620 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4179423-A | TERTIARY AMINE, TRIOL, TRICARBOXYLIC ACID ANHYDRIDE | SCHENECTADY CHEMICALS, INC. (US) | 1979-12-18 | — | — | US | claimed |
| US-9914709-B2 | Compositions and methods of treating HIV-1 infections using same | YALE UNIVERSITY (US) | 2018-03-13 | — | — | US | disclosed |
| US-9631045-B2 | Polycarbodiimides having onium salt groups | PPG INDUSTRIES OHIO, INC. (US) | 2017-04-25 | — | — | US | disclosed |
| US-8981005-B2 | Coating compositions that include onium salt group containing polycarbodiimides | PPG INDUSTRIES OHIO, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-20140378443-A1 | Novel Compositions and Methods of Treating HIV-1 Infections Using Same | YALE UNIVERSITY | 2014-12-25 | — | — | US | disclosed |
| US-20100204515-A1 | POLYCARBODIIMIDES HAVING ONIUM SALT GROUPS | PPG INDUSTRIES OHIO, INC. (US) | 2010-08-12 | — | — | US | disclosed |
| US-20100204414-A1 | COATING COMPOSITIONS THAT INCLUDE ONIUM SALT GROUP CONTAINING POLYCARBODIIMIDES | PPG INDUSTRIES OHIO, INC. (US) | 2010-08-12 | — | — | US | disclosed |
| EP-1301572-B1 | AN ARTICLE HAVING A CHIP-RESISTANT ELECTRODEPOSITED COATING AND A PROCESS FOR FORMING AN ELECTRODEPOSITED COATING | PPG IND OHIO INC (US) | 2005-09-07 | — | — | EP | disclosed |
| CN-1665858-A | Cathodic electrocoating compositions containing morpholine dione blocked polyisocyanate crosslinkers | DU PONT (US) | 2005-09-07 | — | — | CN | disclosed |
| EP-1082394-B1 | A PROCESS FOR FORMING A TWO-COAT ELECTRODEPOSITED COMPOSITE COATING, THE COMPOSITE COATING AND CHIP RESISTANT ELECTRODEPOSITED COATING COMPOSITION | PPG IND OHIO INC (US) | 2004-09-15 | — | — | EP | disclosed |
| EP-0303555-B1 | Preparation of a metallic chelate of ethanol aminophosphoric acid and medicament | KOEHLER CHEMIE DR FRANZ (DE) | 1994-06-15 | — | — | EP | disclosed |
| EP-0426826-B1 | SUBSTITUTED ISOXAZOLIDINES AND ISOXAZOLINES | PHARMACIA AB (SE) | 1994-04-27 | — | — | EP | disclosed |
| US-5212305-A | Cyclization and forming a carbon-nitrogen bond | KABI PHARMACIA AKTIBOLAG (SE) | 1993-05-18 | — | — | US | disclosed |
| US-5155220-A | Simplified production of plaque inhibitor | KABI PHARMACIA AKTIEBOLAG (SE) | 1992-10-13 | — | — | US | disclosed |
| EP-0426826-A1 | SUBSTITUTED ISOXAZOLIDINES AND ISOXAZOLINES. | PHARMACIA AB (SE) | 1991-05-15 | — | — | EP | disclosed |
| WO-1990014342-A1 | SUBSTITUTED ISOXAZOLIDINES AND ISOXAZOLINES | PHARMACIA AB (SE) | 1990-11-29 | — | — | WO | disclosed |
| EP-0303555-A2 | Preparation of a metallic chelate of ethanol aminophosphoric acid and medicament | Dr. Franz Köhler Chemie GmbH (DE) | 1989-02-15 | — | — | EP | disclosed |
| US-4582904-A | REACTING ORGANIC HYDROXY COMPOUND WITH AMMONIA OR AMINE COMPOUND | AIR PRODUCTS AND CHEMICALS, INC. (US) | 1986-04-15 | — | — | US | disclosed |
| US-4560798-A | SELF CONDENSATION OF ETHANOLAMINE;HIGH SELECTIVITY | AIR PRODUCTS AND CHEMICALS, INC. (US) | 1985-12-24 | — | — | US | disclosed |
| US-4048338-A | Aqueous cosmetic composition containing amine oxides | COLGATE-PALMOLIVE COMPANY (US) | 1977-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140378443-A1 | Novel Compositions and Methods of Treating HIV-1 Infections Using Same | CCR5, CCL5, CX3CR1 | SLC6A2 4284/4885SLC6A3 4218/4885SLC6A4 4641/4885 |
| US-20100204515-A1 | POLYCARBODIIMIDES HAVING ONIUM SALT GROUPS | CA7, HDAC6, HDAC10 | SLC6A2 2010/4885SLC6A3 1101/4885SLC6A4 1157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.